Exosome Diagnostics, a Bio-Techne brand, is a world leader in developing liquid biopsy-based diagnostics. The company has clinical laboratories in Waltham, MA (US) and Munich (DE) to support its diagnostics and biopharma segments.
Exosome Diagnostics’ non-invasive, exosome-based urine test known as the ExoDx™ Prostate test, or EPI, is a risk assessment tool for detection of high-grade prostate cancer in men considering prostate biopsy. The test features a 97% NPV for detection of Gleason 4+3 with a sensitivity of 92%.
It is currently available as a laboratory developed test (LDT) through urologists and primary care physicians in the US and Europe. The test achieved FDA Breakthrough Device designation, is included in the National Comprehensive Cancer Network (NCCN) May 2019 guidelines, received a 10-year unlimited General Services Administration (GSA) Award, and is covered by Medicare and other private insurers. Learn about the ExoDx Prostate Test in this short video.
Exosome Diagnostics empowers the world’s leading biopharma companies' with biomarker discovery, translational research, and clinical trials through partnerships. The company offers services using RNA, cell-free DNA, and proteins with their proprietary technology to explore and identify biomarkers. It is the first and only company that can simultaneously isolate and analyze exosomal RNA and cfDNA in a single step to achieve highest sensitivity for detecting rare mutations. Exosome Diagnostics is a core provider to support advancement of patient care. Visit us: https://www.exosomedx.com/.